SCHEDULE: Deep Track Capital Reports 0% Stake in Dianthus Therapeutics
Schedule 13G Amendment
Deep Track Capital and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Dianthus Therapeutics Inc. as of September 30, 2025.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 1 to Schedule 13G.
- As of September 30, 2025, the reporting persons beneficially own 0 shares of Dianthus Therapeutics Inc. Common Stock.
- This represents 0% of the outstanding class of securities.
- The total Common Stock outstanding for Dianthus Therapeutics Inc. was 38,664,361 shares as of September 11, 2025, according to the issuer's Prospectus.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, reporting a 0% stake. It does not contain information that would inherently sway sentiment positively or negatively regarding the issuer's performance or prospects.
Future Outlook
Not applicable, as this filing is a disclosure of past beneficial ownership status.
Industry Context
This is a routine regulatory disclosure of institutional ownership, indicating a complete divestment or reduction to zero beneficial ownership by the reporting entities. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders are informed of a change in institutional ownership, specifically a divestment to 0% by Deep Track Capital and its affiliates.
Key Dates
| Date | Description |
|---|---|
| September 11, 2025 | Date of issuer's Prospectus filing with the SEC, stating 38,664,361 Common Stock outstanding. |
| September 30, 2025 | Date of event which requires filing of this statement, and the 'as of' date for reported ownership. |
| November 14, 2025 | Date the Schedule 13G/A was signed and filed. |
Keywords
Dianthus Therapeutics, Deep Track Capital, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.